Wednesday, 6 March 2019

Alnylam's gene-silencing drug meets main goal in late-stage study

Alnylam Pharmaceuticals Inc said on Wednesday its gene-silencing drug for treating a rare, painful disease met the main goal in a late-stage trial.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)